Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models.
Kristin StirmPeter LearyDaria WüstDominique StarkNicole JollerUfuk KarakusOnur BoymanAlexandar TzankovAnne MüllerPublished in: Journal for immunotherapy of cancer (2023)
The combined data implicate Tregs as a potential therapeutic target in DLBCL, especially in combination with other immunotherapies.